Vista Finance LLC Acquires Shares of 1,041 Medpace Holdings, Inc. (NASDAQ:MEDP)

Vista Finance LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 1,041 shares of the company's stock, valued at approximately $346,000. Medpace accounts for approximately 0.4% of Vista Finance LLC's portfolio, making the stock its 29th biggest position.

A number of other hedge funds also recently made changes to their positions in MEDP. Centaurus Financial Inc. lifted its holdings in Medpace by 2.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock worth $505,000 after purchasing an additional 29 shares in the last quarter. Lindenwold Advisors INC lifted its holdings in Medpace by 1.6% in the 3rd quarter. Lindenwold Advisors INC now owns 2,026 shares of the company's stock worth $676,000 after purchasing an additional 32 shares in the last quarter. Stephens Inc. AR lifted its holdings in Medpace by 4.9% in the 4th quarter. Stephens Inc. AR now owns 752 shares of the company's stock worth $250,000 after purchasing an additional 35 shares in the last quarter. M&T Bank Corp lifted its holdings in Medpace by 1.2% in the 3rd quarter. M&T Bank Corp now owns 3,199 shares of the company's stock worth $1,068,000 after purchasing an additional 37 shares in the last quarter. Finally, Custom Index Systems LLC lifted its holdings in Medpace by 3.0% in the 4th quarter. Custom Index Systems LLC now owns 1,290 shares of the company's stock worth $429,000 after purchasing an additional 37 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently commented on the company. William Blair reissued an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Robert W. Baird upped their price objective on Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Baird R W cut Medpace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 23rd. Finally, TD Cowen decreased their price objective on Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $381.44.

Medpace Trading Up 1.0 %

Shares of NASDAQ MEDP traded up $3.24 during trading hours on Wednesday, hitting $344.01. 353,871 shares of the company traded hands, compared to its average volume of 276,802. The stock has a market capitalization of $10.48 billion, a price-to-earnings ratio of 27.24, a price-to-earnings-growth ratio of 3.76 and a beta of 1.36. The company's 50 day moving average price is $343.26 and its 200 day moving average price is $347.75. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.